Published in Neuropsychopharmacology on August 23, 2006
Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull (2008) 2.09
The environment and susceptibility to schizophrenia. Prog Neurobiol (2010) 1.94
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology (2008) 1.49
Genes, cognition and brain through a COMT lens. Neuroscience (2009) 1.43
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull (2008) 1.27
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res (2008) 1.13
Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness. Front Psychiatry (2013) 1.09
Gene-environment interactions in severe mental illness. Front Psychiatry (2014) 1.09
Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci (2009) 1.06
A classification of sociomedical health indicators: perspectives for health administrators and health planners. Int J Health Serv (1976) 1.04
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2008) 1.03
From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry (2009) 1.02
The prevention of schizophrenia--what can we learn from eco-epidemiology? Schizophr Bull (2010) 1.02
Biological implications of gene-environment interaction. J Abnorm Child Psychol (2008) 1.01
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) (2008) 1.00
Animal models of gene-environment interactions in schizophrenia. Behav Brain Res (2009) 0.98
Genetically informative research on adolescent substance use: methods, findings, and challenges. J Am Acad Child Adolesc Psychiatry (2010) 0.96
The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry (2008) 0.95
COMT but not serotonin-related genes modulates the influence of childhood abuse on anger traits. Genes Brain Behav (2009) 0.94
Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry (2013) 0.94
Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology (2010) 0.93
AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology (2011) 0.92
Cannabis use and cognition in schizophrenia. Front Hum Neurosci (2009) 0.91
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull (2015) 0.91
COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology (2013) 0.89
Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. Neuropsychopharmacology (2015) 0.87
Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus (2015) 0.85
Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia. Front Pharmacol (2012) 0.85
Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology (2012) 0.84
From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull (2009) 0.84
The effect of cannabis use on memory function: an update. Subst Abuse Rehabil (2013) 0.83
Comprehensive behavioural analysis of Long Evans and Sprague-Dawley rats reveals differential effects of housing conditions on tests relevant to neuropsychiatric disorders. PLoS One (2014) 0.82
What does a mouse tell us about neuregulin 1-cannabis interactions? Front Cell Neurosci (2013) 0.82
Gene x environment interactions in schizophrenia and bipolar disorder: evidence from neuroimaging. Front Psychiatry (2013) 0.80
Effects of Δ-THC on Working Memory: Implications for Schizophrenia? Prim psychiatry (2009) 0.80
Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug Alcohol Depend (2009) 0.79
COMT-by-sex interaction effect on psychosis proneness. Biomed Res Int (2015) 0.79
Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function. PLoS One (2013) 0.79
Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. Psychiatr Q (2009) 0.78
A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development. Subst Abuse Treat Prev Policy (2010) 0.78
AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry (2016) 0.77
The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry (2014) 0.77
GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology (2015) 0.76
Cannabis and schizophrenia spectrum disorders: a review of clinical studies. Indian J Psychol Med (2009) 0.76
Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse (2016) 0.75
Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings. Eur Arch Psychiatry Clin Neurosci (2013) 0.75
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. Pharmaceuticals (Basel) (2010) 0.75
The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology (Berl) (2015) 0.75
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 4.63
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (2011) 3.84
The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev (2010) 3.77
Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull (2012) 3.46
"Schizophrenia" does not exist. BMJ (2016) 3.34
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (2004) 2.93
Cannabis use and vulnerability for psychosis in early adolescence--a TRAILS study. Addiction (2013) 2.46
Ethnic density of neighborhoods and incidence of psychotic disorders among immigrants. Am J Psychiatry (2007) 2.45
Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry (2006) 2.44
A salience dysregulation syndrome. Br J Psychiatry (2009) 2.23
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
The effects of FreeSurfer version, workstation type, and Macintosh operating system version on anatomical volume and cortical thickness measurements. PLoS One (2012) 2.18
Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J Psychiatry (2010) 2.10
Does the urban environment cause psychosis? Br J Psychiatry (2004) 2.10
Developing limits for driving under cannabis. Addiction (2007) 2.09
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol (2005) 2.00
Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol (2005) 1.96
Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophr Bull (2009) 1.93
The environment and schizophrenia: the role of cannabis use. Schizophr Bull (2005) 1.90
Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. Schizophr Bull (2005) 1.88
Children's health-related quality of life, neighbourhood socio-economic deprivation and social capital. A contextual analysis. Soc Sci Med (2003) 1.86
Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry (2010) 1.81
Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res (2002) 1.80
Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin Psychol Rev (2007) 1.78
Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res (2007) 1.77
Cannabis use and expression of mania in the general population. J Affect Disord (2006) 1.76
Prediction of transition from common adolescent bipolar experiences to bipolar disorder: 10-year study. Br J Psychiatry (2010) 1.75
Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry (2006) 1.74
Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry (2008) 1.70
Efficacy of mindfulness-based cognitive therapy in relation to prior history of depression: randomised controlled trial. Br J Psychiatry (2012) 1.70
Childhood trauma as a cause of psychosis: linking genes, psychology, and biology. Can J Psychiatry (2013) 1.66
Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction (2012) 1.65
Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res (2005) 1.64
Childhood trauma and emotional reactivity to daily life stress in adult frequent attenders of general practitioners. J Psychosom Res (2006) 1.63
Pediatric illness severity measures predict delirium in a pediatric intensive care unit. Crit Care Med (2008) 1.60
Psychopathological mechanisms linking childhood traumatic experiences to risk of psychotic symptoms: analysis of a large, representative population-based sample. Schizophr Bull (2014) 1.59
Pediatric delirium in critical illness: phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit. Intensive Care Med (2007) 1.57
The BDNF Val(66)Met x 5-HTTLPR x child adversity interaction and depressive symptoms: An attempt at replication. Am J Med Genet B Neuropsychiatr Genet (2008) 1.55
Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes. Br J Psychiatry (2005) 1.55
Determinants of occurrence and recovery from hallucinations in daily life. Soc Psychiatry Psychiatr Epidemiol (2002) 1.53
The epigenome and postnatal environmental influences in psychotic disorders. Soc Psychiatry Psychiatr Epidemiol (2014) 1.51
Effectively working on rehabilitation goals: 24-month outcome of a randomized controlled trial of the Boston psychiatric rehabilitation approach. Can J Psychiatry (2011) 1.51
Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity--implications for diagnosis and ultra-high risk research. Schizophr Bull (2012) 1.50
Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. Annu Rev Clin Psychol (2010) 1.44
Catatonia in DSM-5. Schizophr Res (2013) 1.43
Gender differences in incidence and age at onset of mania and bipolar disorder over a 35-year period in Camberwell, England. Am J Psychiatry (2005) 1.42
Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol (2007) 1.42
Managing complex patients on a medical psychiatric unit: an observational study of university hospital costs associated with medical service use, length of stay, and psychiatric intervention. J Psychosom Res (2009) 1.40
Impact of psychological trauma on the development of psychotic symptoms: relationship with psychosis proneness. Br J Psychiatry (2006) 1.40
Jaspers was right after all--delusions are distinct from normal beliefs. Against. Br J Psychiatry (2003) 1.40
Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun (2010) 1.36
Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry (2012) 1.35
Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol (2010) 1.34
A therapeutic application of the experience sampling method in the treatment of depression: a randomized controlled trial. World Psychiatry (2014) 1.33
Affective dysregulation and reality distortion: a 10-year prospective study of their association and clinical relevance. Schizophr Bull (2009) 1.32
Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry (2010) 1.32
Emotions, self-esteem, and paranoid episodes: an experience sampling study. Br J Clin Psychol (2011) 1.32
Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol Med (2007) 1.31
Psychiatric diagnosis revisited: towards a system of staging and profiling combining nomothetic and idiographic parameters of momentary mental states. PLoS One (2013) 1.31
Childhood trauma and psychosis: a case-control and case-sibling comparison across different levels of genetic liability, psychopathology, and type of trauma. Am J Psychiatry (2011) 1.30
A time-lagged momentary assessment study on daily life physical activity and affect. Health Psychol (2011) 1.29
Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res (2010) 1.26
Data gathering: biased in psychosis? Schizophr Bull (2005) 1.24
Mindfulness training increases momentary positive emotions and reward experience in adults vulnerable to depression: a randomized controlled trial. J Consult Clin Psychol (2011) 1.23
Childhood victimisation and developmental expression of non-clinical delusional ideation and hallucinatory experiences: victimisation and non-clinical psychotic experiences. Soc Psychiatry Psychiatr Epidemiol (2006) 1.23
Effect of COMT Val158Met polymorphism on the Continuous Performance Test, Identical Pairs Version: tuning rather than improving performance. Am J Psychiatry (2005) 1.23
Evidence that moment-to-moment variation in positive emotions buffer genetic risk for depression: a momentary assessment twin study. Acta Psychiatr Scand (2007) 1.22
Refractory agitation as a marker for pediatric delirium in very young infants at a pediatric intensive care unit. Intensive Care Med (2010) 1.22
The structure of the extended psychosis phenotype in early adolescence--a cross-sample replication. Schizophr Bull (2009) 1.21
On the utility of diagnostic instruments for pediatric delirium in critical illness: an evaluation of the Pediatric Anesthesia Emergence Delirium Scale, the Delirium Rating Scale 88, and the Delirium Rating Scale-Revised R-98. Intensive Care Med (2011) 1.20
Validation of remission criteria for schizophrenia. Am J Psychiatry (2006) 1.19
Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res (2006) 1.19
Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res (2007) 1.19
Evidence that onset of psychosis in the population reflects early hallucinatory experiences that through environmental risks and affective dysregulation become complicated by delusions. Schizophr Bull (2010) 1.18
An observational, "real life" trial of the introduction of assertive community treatment in a geographically defined area using clinical rather than service use outcome criteria. Soc Psychiatry Psychiatr Epidemiol (2007) 1.18
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry (2010) 1.17
A real-life observational study of the effectiveness of FACT in a Dutch mental health region. BMC Psychiatry (2008) 1.17
Rumination and worrying as possible mediators in the relation between neuroticism and symptoms of depression and anxiety in clinically depressed individuals. Behav Res Ther (2008) 1.15
Emotional experience in negative symptoms of schizophrenia--no evidence for a generalized hedonic deficit. Schizophr Bull (2011) 1.15
Children's mental health service use, neighbourhood socioeconomic deprivation, and social capital. Soc Psychiatry Psychiatr Epidemiol (2003) 1.15